An FDA advisory panel recommended that compounding pharmacies be allowed to produce the peptide epitalon, while narrowly voting against manufacturing emideltide. The votes followed earlier panel consideration that supported allowing compounding of four other peptides, putting Health Secretary Robert F. Kennedy Jr. closer to expanding access to certain unapproved compounded compounds. The decision comes amid heightened attention to peptide use in the US, fueled in part by social media-driven demand. While the panel’s recommendation for epitalon advances availability, the negative vote on emideltide reflects persistent safety or efficacy concerns. The narrow split underscores how advisory committees balance patient access considerations against the evidentiary threshold for manufacturing unapproved compounds through compounding pharmacies. The next step is how the broader regulatory process translates committee recommendations into policy and whether additional data or safeguards are required.